Kalaris Therapeutics (NASDAQ:KLRS) Upgraded to “Hold” at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

KLRS has been the subject of several other research reports. Morgan Stanley initiated coverage on shares of Kalaris Therapeutics in a research note on Thursday, April 16th. They set an “overweight” rating and a $14.00 price objective for the company. Citizens Jmp reduced their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Wedbush began coverage on shares of Kalaris Therapeutics in a research report on Thursday, May 14th. They set an “outperform” rating and a $17.00 target price on the stock. Finally, Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.60.

Kalaris Therapeutics Stock Down 4.7%

NASDAQ KLRS opened at $4.44 on Friday. The firm has a market cap of $105.63 million, a PE ratio of -2.07 and a beta of 0.15. The company has a 50 day moving average price of $5.50 and a 200 day moving average price of $7.50. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06. On average, equities research analysts anticipate that Kalaris Therapeutics will post -2.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Srinivas Akkaraju bought 244,300 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $4.83 per share, with a total value of $1,179,969.00. Following the transaction, the director owned 2,224,147 shares in the company, valued at approximately $10,742,630.01. This trade represents a 12.34% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 68.10% of the company’s stock.

Institutional Trading of Kalaris Therapeutics

Large investors have recently bought and sold shares of the stock. Nano Cap New Millennium Growth Fund L P purchased a new stake in Kalaris Therapeutics during the 4th quarter worth approximately $34,000. Barclays PLC purchased a new stake in Kalaris Therapeutics during the 4th quarter worth approximately $51,000. Johnson Financial Group Inc. purchased a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at $58,000. XTX Topco Ltd purchased a new stake in shares of Kalaris Therapeutics in the 2nd quarter valued at $65,000. Finally, WealthTrust Asset Management LLC acquired a new stake in shares of Kalaris Therapeutics in the first quarter worth $72,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.